In simple terms, Meridian Bioscience, Inc. has 43.828 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.566% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.021%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.009%. This tells us they're good at keeping money after all costs.
Return on Investments
The company's asset efficiency, represented by a robust -0.006% return, is a testament to Meridian Bioscience, Inc.'s adeptness in optimizing resource deployment. Meridian Bioscience, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.007%. Furthermore, the proficiency of Meridian Bioscience, Inc. in capital utilization is underscored by a remarkable 0.017% return on capital employed.
Stock Prices
Meridian Bioscience, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $32.24, while its low point bottomed out at $31.865. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Meridian Bioscience, Inc.'s stock market.
Company general description and statistics
Sector: Healthcare
Industry: Diagnostics & Research
CEO:Mr. John Kenny
Full-time employees:690
City:Cincinnati
Address:3471 River Hills Dr
IPO:1986-07-29
CIK:0000794172
Website:
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests for Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, isothermal reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
